TY - JOUR AU - KULKARNI, ALPANA AU - BACHHAV, RITESH AU - HOL, VISHAL AU - SHETE, SWAPNIL PY - 2020/05/07 Y2 - 2024/03/29 TI - CO-CRYSTALS OF ACTIVE PHARMACEUTICAL INGREDIENT-IBUPROFEN LYSINE JF - International Journal of Applied Pharmaceutics JA - Int J App Pharm VL - 12 IS - 3 SE - Original Article(s) DO - 10.22159/ijap.2020v12i3.36463 UR - https://journals.innovareacademics.in/index.php/ijap/article/view/36463 SP - 22-32 AB - <p><strong>Objective: </strong>Co-crystal is defined as a crystalline complex of two or more neutral molecules bound together primarily by hydrogen bonding or other non-covalent interactions. The pharmaceutical co-crystal involves crystal lattice arrangement between an Active Pharmaceutical Ingredient (API) with another pharmaceutically acceptable molecule. Co-crystals of API are preferred since they depict improved solubility, dissolution, stability, compressibility in comparison with API. Ibuprofen lysine (IL), frequently used analgesic and the anti-inflammatory drug has poor aqueous solubility and compressibility. This work shows the feasibility and optimal conditions for the preparation of co-crystals of ibuprofen lysine using Polyvivylpyrrolidone K25 (PK 25) and Polyvivylpyrrolidone K30 (PK 30) as co-formers.</p><p><strong>Methods: </strong>In this study, we prepared and studied the solubility, drug content, flow properties, physical stability of novel co-crystal, consisting of IL and PK 25/PK 30. The co-crystal IL: PK 30 (at a molar ratio of 0.29:0.5) and IL: PK 25 (at a molar ratio of 0.58:1) were characterized by X-ray analysis, infrared spectroscopy and thermal analysis. Furthermore, the tablet formulations of the co-crystals were subjected to <em>in vitro</em> dissolution and <em>in vivo</em> analgesic activity, with the goal of comparing the co-crystals with IL and the marketed tablet of ibuprofen (Brufen®) respectively.</p><p><strong>Results: </strong>The IL: PK co-crystals demonstrated superior solubility and the dissolution properties over IL. The compression properties of the co-crystals were similar to IL. The co-crystals exhibited higher analgesic activity than the marketed tablet.&nbsp;</p><p><strong>Conclusion: </strong>The results indicated the use of PK 25 and PK 30 as safe and promising co-crystal formers.</p> ER -